Randomized Trial: Ibrutinib Regimens vs.Chemoimmunotherapy in Older Patients with Untreated CLL

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Ibrutinib vs Standard of Care in Front-Line Treatment of Older Patients With Chronic Lymphocytic Leukemia – The ASCO Post (free) AND Ibrutinib Regimens Have Superior PFS Compared With Chemoimmunotherapy in Older Patients With Untreated CLL – AJMC (free)